Brodalumab efficacy in psoriasis patients with inadequate response to IL-23 or IL-12/23 inhibitors: multicenter Italian retrospective analysis - IL PSO (Italian Landscape Psoriasis)
Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction: The use of brodalumab in patients with psoriasis who have failed other biologic drugs is an under-explored topic; A variable percentage of patients still experience primary therapeutic failure, incomplete response, or progressive loss of treatment efficacy (secondary therapeutic failure). In this context, switching treatments among different mechanisms of action has been explored in previous studies conducted on psoriatic patients. However, criteria providing a clear clinical rationale for such transitions are lacking, and no clear guidance is provided by international guidelines to date. Objectives: To evaluate the safety and the efficacy of brodalumab in a subgroup of psoriasis patients who already failed anti-IL23 or anti-IL12/23 treatment. Methods: We retrospectively evaluated, using the PASI and DLQI index, a cohort of 23 patients with psoriasis who underwent a change of therapy with brodalumab exclusively following primary or secondary therapeutic failure of anti-IL-23 or anti-12/23 drugs. Results: The mean PASI decreased significantly following the introduction of brodalumab after 4 weeks of treatment, and continued to decrease at 16 and 36 weeks, reaching the nadir at 52 weeks (baseline PASI baseline= 14.6 ± 9.2 vs. 52 weeks PASI= 1.1 ± 1.8; p <0.001). The 63.6% of patients reached PASI 100 just after 16 weeks. The same trend of improvement was also observed for the DLQI. The adverse effects observed in our study population were generally mild. Conclusions: Our results are in line with the current literature and suggest that patients who have failed therapy with IL-23 or IL-12/23 inhibitors may benefit from switching to brodalumab, which could be considered a good choice for patients who need a rapid resolution of the inflammatory skin condition.
Authors: Diego Orsini, Maria Concetta Fargnoli, Martina Burlando, Anna Campanati, Elena Campione, Claudio Guarneri, Alessandra Narcisi, Paolo Pella, Paolo Romita, Massimo Travaglini, Leonardo Zichichi, Luisa Maria Halina Arancio, Chiara Assorgi, Ginevra Baggini, Riccardo Balestri, Luca Bianchi, Alexandra Maria Giovanna Brunasso, Anna Elisabetta Cagni, Giacomo Caldarola, Gianluca Calianno, Antonio Carpentieri, Martino Carriero, Andrea Carugno, Franco Cona, Antonio Costanzo, Emanuele Cozzani, Giacomo Dal Bello, Paolo Dapavo, Annunziata Dattola, Antonio Di Tano, Federico Diotallevi, Marianna Donnarumma, Elena De Col, Maria Esposito, Carmen Silvia Fiorella, Marco Galluzzo, Francesca Graziola, Giovanni Carlo Lazzaro Danzuso, Agostina Legori, Matteo Licciardello, Viviana Lora, Piergiorgio Malagoli, Matteo Megna, Federica Mola, Gaia Moretta, Andrea Muracchioli, Attilia Musumeci, Maria Letizia Musumeci, Gianluca Pagnanelli, Vincenzo Panasiti, Eugenio Provenzano, Simone Ribero, Daniele Rizzo, Marco Rubatto, Oriele Sarno, Davide Strippoli, Fabrizio Vaira, Dario Graceffa
Institutions: San Gallicano Hospital, University of Genoa, Marche Polytechnic University, University of Rome Tor Vergata, University of Messina, IRCCS Humanitas Research Hospital, Ospedale degli Infermi, University of Bari Aldo Moro, Ospedale A. Perrino, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Sapienza University of Rome, Azienda Sanitaria Locale Alessandria, Ospedale Villa Scassi, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Azienda Socio Sanitaria Territoriale di Cremona, University of Insubria, Azienda Ospedaliera Carlo Poma, University of Turin, Azienda Sanitaria Locale Salerno, University of L'Aquila, Azienda Ospedaliero Universitaria Maggiore della Carita, University of Milan, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Ospedale Koelliker, IRCCS Policlinico San Donato, University of Naples Federico II, Azienda Socio Sanitaria Territoriale Lariana, Istituto Dermopatico dell'Immacolata, University of Catania, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco", Campus Bio Medico University Hospital, Azienda Ospedaliera di Cosenza, Candiolo Cancer Institute, Azienda Ospedaliera S.Giuseppe Moscati, Alessandro Manzoni Hospital, Aziende Socio Sanitarie Territoriali di Lecco, IRCCS Ospedale San Raffaele
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
Funders: Pfizer, Sun Pharma
OpenAlex ID: W4415737549